Abstract: TH-PO1140
Proenkephalin in Critically Ill Patients with COVID-19
Session Information
- COVID-19
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Ostermann, Marlies, Guy's and St Thomas' NHS Foundation Trust, London, London, United Kingdom
- Hartmann, Oliver, SphingoTec GmbH, Hennigsdorf, Brandenburg, Germany
- Schulte, Janin, SphingoTec GmbH, Hennigsdorf, Brandenburg, Germany
- D'Amato, Fabiola, Guy's and St Thomas' NHS Foundation Trust, London, London, United Kingdom
- Vas, Kyma Morera, Guy's and St Thomas' NHS Foundation Trust, London, London, United Kingdom
- Lorah, Shelley, Guy's and St Thomas' NHS Foundation Trust, London, London, United Kingdom
- Radcliffe, Gillian, Guy's and St Thomas' NHS Foundation Trust, London, London, United Kingdom
- Lumlertgul, Nuttha, King Chulalongkorn Memorial Hospital, Bangkok, Bangkok, Thailand
Group or Team Name
- Sphingotec Penkid and GSST Research Team.
Background
There is growing evidence for proenkephalin A 119-159 (penKid) as an accurate biomarker to estimate kidney function and detect acute kidney injury (AKI) in various patient cohorts but its role in critically ill patients with COVID-19 has not been described.
Methods
We recruited critically ill adult patients with COVID-19 admitted to the intensive care unit (ICU) in a University Hospital in London, UK, between August 2020 and January 2022 and measured plasma penKid levels daily for up to seven days. PenKid was compared in patients with and without AKI according to Kidney Disease Improving Global Outcomes (KDIGO) criteria and analyzed for prediction of need for renal replacement therapy (RRT).
Results
Ninety-one critically ill adult patients (34 females, 57 males; mean age 51 years; mean SOFA score 6) were admitted to the ICU. Sixty patients (66%) required mechanical ventilation, 36 patients (40%) had AKI at enrolment of whom 21 received RRT. Twenty-eight day mortality was 15.4%. Among the survivors, six patients (8%) were RRT dependent on day 28. During the first week after enrolment, plasma penKid was increased with stages of AKI and highest penKid levels were observed in patients receiving RRT (Figure 1). Plasma penKid on day 1 at ICU identified patients who were RRT dependent on day 28 (Figure 2).
Conclusion
In critically ill adults with COVID-19, penKid is a measure of kidney function, diagnoses AKI and predicts RRT dependence at 28 days.
penKid by AKI stage
penKid by RRT dependency on day 28